Anti-Synthetase Syndrome
New anti-synthetase syndrome research, summarized each month in plain language.
2026 so far: January 2026 to September 2026 updates centered on ASyS-ILD, with early treatment signals and new risk-tracking tools alongside ongoing relapse and infection concerns and efforts to make antibody test results more dependable. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- ILD treatment signals. More ILD treatment experiments appeared, alongside clearer safety trade-offs.
- Steroid tapering risks. Real-world data linked 6-month steroid dose to infection and flare patterns.
- Tracking lung course. Studies increasingly separated ILD into distinct trajectories and risk groups.
- Risk markers. Ro52 and lung markers recurred; pulmonary hypertension emerged as a major outcome signal.
- Antibody test clarity. Multiple studies showed weak positives often fail confirmation; new interpretation tools emerged.
New
September 2026
- Lung medicine pattern. Calcineurin inhibitors plus steroids often matched stable or improved lung disease.
- Relapse risk. Relapses were often reported even with ongoing lung treatment.
- Combination therapy signal. A very small series suggested benefit but also reported infections.
- Pulmonary hypertension risk. Pulmonary hypertension was linked to worse survival in registry data.
August 2026
- Lung course patterns. Studies grouped lung disease into patterns, including a higher-risk fibrosis type.
- Anti-Ro52 and lungs. Anti-Ro52 was linked to lung involvement, not clearly to outlook.
- Rituximab target signal. Larger early B-cell drops were linked with later improvement.
- Relapse risk marker. Relapse was more common in people with anti-ARS antibodies.
July 2026
- CT lung burden. CT measures of fibrosis and lung burden linked to higher death risk.
- Antibody-linked lung risk. Jo-1 and Ro52 antibodies were linked with more lung involvement.
- Immune cell marker. One immune cell marker tracked disease activity in early data.
- Uncommon complications. Single-patient reports described rare eye, liver, brain, and gut issues.
June 2026
- Lung course signals. Chest CT patterns were linked to different breathing test trends.
- Mortality risk score. A five-item score estimated mortality risk from routine data.
- Antibody panel clarity. New scoring methods made positive antibody panels easier to interpret.
May 2026
- Steroid dose by 6 months. In one ASyS-ILD cohort, reaching a lower steroid dose by 6 months was linked to fewer serious infections requiring hospitalization.
- Anti-Ro52 and lung outcomes. In one ASyS-ILD center, anti-Ro52 positivity was linked to a higher chance of lung relapse or lung-related death.
- Weak-positive antibody results. In a multi-lab study, many weak-positive anti-synthetase antibody results were not confirmed when retested with stricter methods.
April 2026
- Early lung treatment signal. In a small follow-up group that included anti-synthetase syndrome, a B-cell–targeted medicine given with glucocorticoids was followed by improved lung function and walking distance.
- CT tracks lung function. Across studies, CT scan measurements of lung disease often changed in the same direction as breathing test results.
- ILD can return after improvement. One study reported that interstitial lung disease (ILD) returned in about 1 in 3 people after initial improvement.
- B-cell stress and interferon signals. Lab studies found stress-related and interferon-related signals in B cells.
March 2026
- Cancer risk by antibody type. Some studies found higher cancer rates in anti-synthetase syndrome, with anti-OJ showing a higher signal in one cohort and a similar pattern in a review.
- Breathing test change and survival. In myositis-related interstitial lung disease, a forced vital capacity drop of at least 5% over 1 year was linked to higher 10-year mortality in one analysis.
- Confirming antibody results. Some initial antisynthetase antibody screening positives were not confirmed on follow-up testing.
February 2026
- New immune treatments. In small reports of hard-to-treat anti-synthetase syndrome, newer immune-targeting treatments were linked with better muscle strength and sometimes lower corticosteroid use.
- Safety signals reported. Bispecific immune therapy was linked with rapid improvement in refractory disease, and reports also described side effects such as cytokine release syndrome and respiratory infections.
- Why antibody tests differ. A newer antibody test method agreed more closely with a reference test than line blot testing, which helps explain why results can differ across test types.
- Lung outlook and tracking. In interstitial lung disease, autoimmune-related cases had better survival than idiopathic pulmonary fibrosis, and breathing-test trends aligned more with diagnosis than with scan pattern.
January 2026
- Lung scarring changes. In some people, lung scarring worsened after muscle symptoms improved.
- Antibody test context. Antibody panels fit best when testing was prompted by suspected myositis.
- Ultrasound vs CT. Lung ultrasound only moderately matched CT scan severity.
- Pregnancy flare link. Pregnancy problems were reported only when the disease flared.
Get the monthly update by email
Subscribe here to receive an email when a new monthly anti-synthetase syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).